<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666000</url>
  </required_header>
  <id_info>
    <org_study_id>PBCAR0191-01</org_study_id>
    <nct_id>NCT03666000</nct_id>
  </id_info>
  <brief_title>Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL</brief_title>
  <official_title>Phase 1/2a, Open-label, Dose-escalation/Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Precision BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Precision BioSciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and&#xD;
      dose-expansion study to evaluate the safety and clinical activity of PBCAR0191 in adults with&#xD;
      r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, nonrandomized, open-label, parallel assignment, dose-escalation, and&#xD;
      dose-expansion study to evaluate the safety and tolerability, find an appropriate dose to&#xD;
      optimize safety and efficacy, and evaluate clinical activity of PBCAR0191 in subjects with&#xD;
      relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin&#xD;
      lymphoma (NHL). Before initiating PBCAR0191, subjects will be administered lymphodepletion&#xD;
      chemotherapy composed of fludarabine and cyclophosphamide. At Day 0 of the Treatment Period,&#xD;
      subjects will receive an intravenous (IV) infusion of PBCAR0191. Subjects who receive a split&#xD;
      dose will also receive an IV infusion of PBCAR0191 on Day 10 and/or Day 14. Subjects may be&#xD;
      considered for retreatment. All subjects are monitored during the treatment period through&#xD;
      Day 28. All subjects who receive a dose of PBCAR0191 will be followed in a separate long-term&#xD;
      follow-up (LTFU) study for 15 years after exiting this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>In each cohort (NHL and B-ALL), up to 6 dose levels will be enrolled and treated sequentially. Within each dose level, up to 6 subjects will be treated with PBCAR0191 using a standard 3 + 3 design. The starting dose of PBCAR0191 will be 3 × 10^5 CAR T cells/kg body weight. Subsequent dose groups will be treated with escalating doses to a maximum dose of 9 × 10^6 CAR T cells/kg. In the absence of DLTs, the dose will be increased using a fixed dose scheme.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity(ies)</measure>
    <time_frame>1 year</time_frame>
    <description>To assess adverse events as dose limiting toxicities as defined by the protocol and CTCAE v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate of Patients</measure>
    <time_frame>1 year</time_frame>
    <description>To assess clinical activity as response in B-ALL by the NCCN Guidelines on ALL (NCCN, 2017) and in NHL by the revised Lugano Classification (Cheson et al, 2016), both reported as objective response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the duration (days) of response from initial response until disease relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the duration (days) of response from Day 0 to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the duration (days) of response from Day 0 to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the duration (days) of response from Day 0 to institution of next therapy</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PBCAR0191, 3 x 10^5 CAR T cells per kg body weight.&#xD;
In this study, PBCAR0191, allogeneic anti-CD19 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia.&#xD;
Route of Administration: Intravenous infusion.&#xD;
Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR0191 infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PBCAR0191, 1 x 10^6 CAR T cells per kg body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PBCAR0191, 3 x 10^6 CAR T cells per kg body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PBCAR0191, 3 x 10^6 CAR T cells per kg body weight as 3 administrations of 1 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PBCAR0191, 6 x 10^6 CAR T cells per kg body weight as 2 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PBCAR0191, 9 x 10^6 CAR T cells per kg body weight as 3 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PBCAR0191</intervention_name>
    <description>Single dose of Allogeneic Anti-CD19 CAR T cells will be infused</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3a</arm_group_label>
    <arm_group_label>Dose Level 3b</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Allogeneic Anti-CD19 CAR T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine is used for lymphodepletion.</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3a</arm_group_label>
    <arm_group_label>Dose Level 3b</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is used for lymphodepletion.</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3a</arm_group_label>
    <arm_group_label>Dose Level 3b</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria*&#xD;
&#xD;
        Criteria for B-ALL:&#xD;
&#xD;
          -  Relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (B-ALL).&#xD;
&#xD;
          -  Philadelphia chromosome positive (Ph+) disease can be eligible if they are intolerant&#xD;
             to tyrosine kinase inhibitor (TKI) therapy or if they have relapsed/refractory&#xD;
             disease.&#xD;
&#xD;
        Criteria for NHL:&#xD;
&#xD;
          -  r/r CD19+ B-cell NHL that is histologically confirmed by archived tumor biopsy tissue&#xD;
             from last relapse and corresponding pathology report. The following types of lymphoma&#xD;
             are included:&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma (DLBCL) including Richter's transformation&#xD;
&#xD;
               -  Primary mediastinal B-cell lymphoma (PMBL)&#xD;
&#xD;
               -  FL including Grade 3B or transformed FL&#xD;
&#xD;
               -  High-grade B-cell lymphoma&#xD;
&#xD;
               -  Small lymphocytic lymphoma (SLL)&#xD;
&#xD;
               -  Mantle cell lymphoma (MCL)&#xD;
&#xD;
          -  Received at least 2 prior chemotherapy-containing regimens. Subjects with SLL must&#xD;
             have previously failed at least 2 lines of chemotherapy/immunotherapy that included&#xD;
             ibrutinib and idelalisib plus rituximab.&#xD;
&#xD;
          -  Measurable or detectable disease according to the Lugano Classification.&#xD;
&#xD;
          -  Criteria for both B-ALL and NHL:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status score of 0 or 1.&#xD;
&#xD;
          -  An estimated life expectancy of at least 12 weeks according to the investigator's&#xD;
             judgment.&#xD;
&#xD;
          -  Seronegative for human immunodeficiency virus antibody (i.e., intact immune function).&#xD;
&#xD;
          -  Subject has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function&#xD;
             defined as:&#xD;
&#xD;
               1. Estimated glomerular filtration rate (eGFR) &gt;50 mL/min/1.73 m2.&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels both&#xD;
                  ≤3 times of upper limit of normal, unless there is suspected disease in the&#xD;
                  liver.&#xD;
&#xD;
               3. Total bilirubin &lt;2.0 mg/dL, except in subjects with Gilbert's syndrome.&#xD;
&#xD;
               4. Platelet count ≥30,000/µL (platelet transfusions acceptable).&#xD;
&#xD;
               5. Left ventricular ejection fraction &gt;45% as assessed by echocardiogram (ECHO) or&#xD;
                  multiple gated acquisition scan performed within 1 month before starting&#xD;
                  lymphodepleting chemotherapy. ECHO results performed within 6 months before&#xD;
                  Screening and at least 28 days after the last cancer treatment may be acceptable&#xD;
                  if the subject has not received any treatment with cardiotoxicity risks.&#xD;
&#xD;
               6. No clinically significant evidence of pericardial effusion or pleural effusion.&#xD;
&#xD;
               7. Baseline oxygen saturation &gt;92% on room air.&#xD;
&#xD;
        Key Exclusion Criteria*&#xD;
&#xD;
        Criteria for B-ALL:&#xD;
&#xD;
          -  Burkitt cell (L3 ALL) or mixed-lineage acute leukemia.&#xD;
&#xD;
          -  Active CNS leukemia.&#xD;
&#xD;
        Criteria for NHL:&#xD;
&#xD;
          -  Active hemolytic anemia.&#xD;
&#xD;
          -  Active CNS lymphoma.&#xD;
&#xD;
          -  Criteria for B-ALL and NHL:&#xD;
&#xD;
          -  Previous malignancy, besides the malignancies of inclusion (B-ALL or NHL), that has a&#xD;
             high risk of relapse in the next 2 years.&#xD;
&#xD;
          -  Uncontrolled and serious fungal, bacterial, viral, protozoal, or other infection.&#xD;
&#xD;
          -  Any form of primary immunodeficiency.&#xD;
&#xD;
          -  Active hepatitis B or C.&#xD;
&#xD;
          -  Uncontrolled cardiovascular disease.&#xD;
&#xD;
          -  Hypertension crisis or hypertensive encephalopathy within 3 months.&#xD;
&#xD;
          -  Concomitant genetic syndrome or any other known bone marrow failure syndrome.&#xD;
&#xD;
          -  Active uncontrolled autoimmune disease requiring active immunosuppression (excluding&#xD;
             subjects needing steroids for physiologic replacement).&#xD;
&#xD;
          -  Received stem cell transplant within 90 days.&#xD;
&#xD;
          -  Active GvHD symptoms.&#xD;
&#xD;
          -  Received systemic biologic agent within 30 days or 5 half-lives.&#xD;
&#xD;
          -  Received systemic immunostimulatory agent within 30 days or 5 half-lives.&#xD;
&#xD;
          -  Radiotherapy within 4 weeks determined on a case-by-case basis.&#xD;
&#xD;
          -  Presence of pleural/peritoneal/pericardial catheter.&#xD;
&#xD;
          -  Received live vaccine within 4 weeks before Screening.&#xD;
&#xD;
          -  Current use of any anticoagulant or antiplatelet therapy.&#xD;
&#xD;
               -  Additional criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monika Vainorius, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Precision BioSciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Precision BioSciences, Inc.</last_name>
    <phone>919-314-5512</phone>
    <email>clinical@precisionbiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research</last_name>
      <phone>626-218-1133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research</last_name>
      <phone>888-663-3488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Hospital Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Solomon, MD</last_name>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </contact>
    <investigator>
      <last_name>Scott Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke P Akard, MD</last_name>
      <email>lakard@ibmtindy.com</email>
    </contact>
    <investigator>
      <last_name>Luke P Akard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <phone>877-338-7425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute (Wayne State University)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhinav Deol, MD</last_name>
      <phone>313-576-8093</phone>
      <email>deola@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Abhinav Deol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona He, MD</last_name>
      <email>fionahe@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Fiona He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - NY Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Van Besien, MD</last_name>
      <phone>646-962-7950</phone>
      <email>kov9001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Koen Van Besien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ran Reshef, MD</last_name>
      <email>rr3036@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ran Reshef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute at Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Olszewski, MD</last_name>
      <email>adam_olszewski@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Olszewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research</last_name>
      <phone>855-761-8004</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

